Calibrator and quality control product of anti-eb virus capsid antigen and early antigen antibody and preparation method thereof
A technology of Epstein-Barr virus and early antigen, applied in the direction of disease diagnosis, material inspection products, instruments, etc., can solve the problems of inability to quantify, inaccurate detection, and unguaranteed quality, and achieve shortened exploration time, simple preparation process, and improved specific effect
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
preparation example Construction
[0039] A kind of preparation method of the calibrator of the capsid antigen of anti-Epstein-Barr virus and the IgA antibody of early antigen, the steps are as follows:
[0040] 1) Select nasopharyngeal carcinoma patient plasma containing Epstein-Barr virus VCA-IgA and EA-IgA antibodies and normal human plasma negative for Epstein-Barr virus VCA-IgA and EA-IgA antibodies by immunofluorescence method, and centrifuge to remove the precipitate respectively;
[0041] 2) Add a calcium chloride water bath to the plasma treated in step 1), centrifuge to take the supernatant, mix the nasopharyngeal carcinoma plasma and normal human plasma in proportion, and filter through a filter membrane to prepare VCA-IgA and EA-IgA antibody calibration products.
[0042] A kind of preparation method of the quality control product of the capsid antigen of anti-Epstein-Barr virus and the IgA antibody of early antigen, the steps are as follows:
[0043] 1) By immunofluorescence method, select nasophar...
Embodiment 1
[0058] The preparation method of embodiment 1 calibrator
[0059] (1) Select plasma, Epstein-Barr virus VCA-IgA and EA-IgA antibodies of nasopharyngeal carcinoma patients with EB virus VCA-IgA titer of 1:1280 and EA-IgA antibody titer of 1:320 by immunofluorescence method (IFA) For negative normal human plasma, centrifuge to remove precipitates and interfering substances;
[0060] (2) Add 18mmol / L calcium chloride to the plasma treated in step (1), place in a constant temperature water bath at 38°C for 2 hours, centrifuge at 10,000rpm for 30 minutes, separate, and take the supernatant. Mix nasopharyngeal carcinoma plasma and normal human plasma at a ratio of 1:8, and filter through 0.2 μm cellulose acetate membrane to prepare VCA-IgA and EA-IgA antibody calibration products;
[0061] (3) Subpackage the prepared calibrator, add preservative and 50g / L lyoprotectant, freeze-dry into lyophilized powder for storage.
Embodiment 2
[0062] The preparation method of embodiment 2 calibrator
[0063] (1) Select plasma, Epstein-Barr virus VCA-IgA and EA-IgA antibodies of nasopharyngeal carcinoma patients with EB virus VCA-IgA titer of 1:800 and EA-IgA antibody titer of 1:220 by immunofluorescence method (IFA) For negative normal human plasma, centrifuge to remove precipitates and interfering substances;
[0064] (2) Add 18mmol / L calcium chloride to the plasma treated in step (1), place in a constant temperature water bath at 35°C for 2 hours, centrifuge at 10,000rpm for 30 minutes, separate, and take the supernatant. Nasopharyngeal carcinoma plasma and normal human plasma were mixed at a ratio of 1:5, and filtered through a 0.2 μm cellulose acetate membrane to obtain VCA-IgA and EA-IgA antibody calibrators;
[0065] (3) Subpackage the prepared calibrator, add preservative and 10g / L lyoprotectant, freeze-dry into lyophilized powder for storage.
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


